Pain Sensitisation in Women with Active Rheumatoid Arthritis: A Comparative Cross-Sectional Study
Table 1
Patient characteristics and medication for the 38 participating rheumatoid arthritis patients.
Characteristics
Median (interquartile range)
Age, years
56 (46, 69)
Disease duration, months
33 (29, 45)
IgM RF seropositive, number (%)
23 (61)
Anti CCP-positive, number (%) ()
21 (58)
Bone erosions on X-Ray, number (%) ()
12 (32)
Clinical assessment of disease activity
DAS28
4.3 (3.6, 5.0)
Tender joints
7 (4, 13)
Swollen joints
5 (3, 11)
CRP mg/L
5.5 (0.5, 14)
VAS Global
50 (29, 64)
HAQ-score ()
0.88 (0.63, 1.75)
Tender points
14 (8, 18)
Medication
Numbers (% of total participating patient group)
Patients on DMARDs
34 (89)
Patients on DMARDs + biologics
14 (37)
Concomitant per oral prednisolone
9 (24)
Treatment with 80 mg i.m/i.art steroid within the last 4 weeks
5 (13)
RF: rheumatoid factor, anti-CCP: anticyclic citrullinated peptide, DAS 28: Disease Activity Score, VAS: visual analog scale, VAS Global: patient global assessment of disease severity as measured on a visual analog scale, DMARDs: disease-modifying antirheumatic drugs, i.m/i.art: intramuscular or intra-articular steroid injections.
